WS Audiology announced that the company generated what it reports as “strong revenue and earnings growth in the first half (H1) of fiscal year 2020/21 (October 1, 2020 – March 31, 2021) in the face of the COVID-19 pandemic.” According to its announcement, WS Audiology has continued to bring innovative products to market and has “upgraded the full-year revenue and profitability outlook.”

Related article: WS Audiology Announces Ranking in 2021 WIPO Report

Highlights H1 2020/21 

  • Revenue grew to EUR 995 million (USD$1.2 billion) (organic growth of 8%), 
  • Normalized EBITDA increased 25% to EUR 236 million (USD $284 million) (24% margin), 
  • Strongest performance in Europe and APAC due to faster market recovery, 
  • New restrictions in January and February in some markets with strong recovery in March including the important North American market, 
  • Strong 9% organic growth in Wholesale and solid 7% organic growth in consumer-facing channels (Retail, Online, and Managed Care), 
  • Good profitability driven by synergy program, cost control, and scalability from volume growth, 
  • Merger integration well on track, 
  • Expectations for strong 2020/21 upgraded. 

“WS Audiology’s strong performance and recovery continued and accelerated in the first half of the 2020/21 fiscal year as we leveraged our diversified sales channels and business models,” said WS Audiology CEO Eric Bernard. “While we faced some headwinds early 2021 due to COVID-19 restrictions, we saw a strong recovery in March and continued to reap the benefits of our strong innovation capabilities with the launches of Signia Xperience and Widex Moment last financial year, and we delivered record-high profitability on the back of our successful integration work.”

All business units improved performance in the first half of 2020/21 despite continued effects of COVID-19 in several markets. Revenue grew to EUR 995 million (USD $1.2 billion) with a normalized EBITDA margin of 24% based on the positive business development and good cost containment. 

“We continued to invest in cutting-edge innovation as we launched Signia Active Pro in the beginning of 2021 and ushered in a new era in our industry as the first to introduce a fully-fledged hearing aid that looks like an earbud,” said Bernard. “And in May, we followed up with the introduction of a new Signia platform, Signia AX (Augmented Xperience). For the first time ever, a hearing aid uses two processors, capturing focus and surrounding sounds independently to create a greater contrast between the two – pulling focus sounds such as a conversation partner closer and placing surrounding sounds slightly further away.

“On the back of the strong performance in the first half of the financial year, we expect to deliver strong performance for the full year driven by our exciting product launches, the roll-out of vaccines across core markets, and a potential release of some pent-up demand.”

Based on the strong development in the first half of the financial year and the positive outlook, WS Audiology says it now expects to generate organic growth of at least 20% and increase normalized EBITDA to at least EUR 460 million (USD $555 million) in 2020/21 (EUR 331 million [USD $399 million]in 2019/20) against previous expectations of generating double-digit organic growth and a normalized EBITDA margin of above 20%. However, it should be noted that market uncertainty remains higher than normal due to the ongoing pandemic, the company says.

Source: WS Audiology